Skip to content
Wednesday, June 4, 2025
Latest:
  • Innovation resident plays key role in groundbreaking heart device research
  • Alzheimer’s disease affects an organism as a whole
  • A new treatment brings a new lease on life
  • Scoliosis: How do you know if you have it?
  • Renewing hope: A global push to improve neonatal outcomes
Baylor College of Medicine Blog Network

  • Home
  • Momentum
    • About Momentum
    • Resources
    • Contributors
      • Taylor Barnes
      • Dana Benson
      • Molly Chiu
      • Julie Garcia
      • Graciela Gutierrez
      • Anna Kiappes
      • Andy Phifer
      • Homa Shalchi
      • Melissa Tucker
    • Contact Us
  • From The Labs
    • About From the Labs
    • Follow From The Labs on Twitter
  • Policywise
    • About PolicyWise
    • Follow @BCMEthics on Twitter
  • The Stitch
    • About The Stitch
  • Progress Notes
    • About Progress Notes
    • Progress Notes Editors
    • Connect With Us
  • bcm.edu
Two slides showing breast cancer cells as blue or green dots on a blue background.
From The Labs

A potential strategy to control MAPK4-dependent cancer growth

August 8, 2023 AKT,  cancer growth,  lung cancer,  MAPK4,  PDK1,  Prostate Cancer,  Research,  triple-negative breast cancer

This study has advanced our understanding of the molecular mechanisms underlying the tumor-promoting activity of MAPK4.

Read More
From The Labs

Targeting MAPK4 may offer a new therapeutic opportunity for TNBC

January 27, 2022 AKT,  cancer therapy,  MAPK4,  PI3K,  PI3K inhibitor,  Research,  triple-negative breast cancer

MAPK4 seems to be involved in promoting triple-negative breast cancer growth and its resistance to certain therapies.

Read More
From The Labs

New evidence supports a cancer-promoting role for enzyme MAPK6

December 6, 2021 cancer growth,  MAPK4,  MAPK6,  mTOR inhibitors,  Research

The findings suggest that therapies that interfere with MAPK6 activity may offer an effective cancer treatment approach.

Read More
From The Labs

Targeting MAPK4 emerges as a promising therapy for prostate cancer

February 23, 2021 Akt pathway,  androgen receptor,  cancer therapy,  castration-resistant prostate cancer,  MAPK4,  Prostate Cancer,  Research

Inhibiting MAPK4 simultaneously inactivated both androgen receptor and AKT and stopped cancer growth in animal models.

Read More

From the Labs: Image of the Month

Blood vessels (magenta) intertwined with metastatic medulloblastoma tumor cells (green) nestled within the protective layers that surround the mouse spinal cord. From the Labs: a closer look at metastatic medulloblastoma

Healthy Habits: A DOC-umentary Series

https://www.youtube.com/watch?v=SlNiMWHUhbc

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951